How do you manage patients with HER2 positive breast cancer who have progressive CNS metastases after prior exposure to pertuzumab, trastuzumab, TDM1, and lapatinib?
Answer from: Medical Oncologist at Community Practice
At our institution we have 3 clinical trials that could be considered but would need more information to match against eligibility criteria.
1. HER2-CLIMB with Tucatanib excludes prior capecitabone. Lapatanib is a relative contraindication depending on duration. This ...
Comments
Medical Oncologist at NYU Winthrop Hospital I would recommend neratinib and capcitabine based ...
I would recommend neratinib and capcitabine based ...